Jason Stubbs

Director - Inpatient Dialysis, Nephrology and Hypertension · University of Kansas School of Medicine

Credentials: · · ·

History

Impact of Phosphaturia on Renal Osteopontin Production and PKD Progression
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3.1M · University of Kansas Medical Center
2019–2029
Preventing Vascular Calcification in Kidney Disease
National Heart, Lung, and Blood Institute · R01
PI · $1.7M · University of Kansas Medical Center
2024–2028
Randomized, Controlled Pilot Study of Rifaximin Therapy in Chronic Kidney Disease
National Institute of Diabetes and Digestive and Kidney Diseases · R21
Contact PI · $421.1K · University of Kansas Medical Center
2016–2019
Impact of Endotoxin on Fibroblast Growth Factor 23 Production by Osteocytes
National Institute of Diabetes and Digestive and Kidney Diseases · R03
Contact PI · $151K · University of Kansas Medical Center
2014–2016

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
Principal investigator · Withdrawn · Early phase 1
Jason Stubbs, MD
2016–2019
Rifaximin Therapy in Chronic Kidney Disease
Principal investigator · Completed · Phase 4
Jason Stubbs, MD
2015–2019
Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease
Principal investigator · Completed
University of Kansas Medical Center
2011–2015
Impact of Vitamin D Therapies on Chronic Kidney Disease
Principal investigator · Completed
University of Kansas Medical Center
2010–2012